Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.cct.2008.10.003
Title: A semi-parametric analysis for identifying Scleroderma patients responsive to an anti-fibrotic agent
Authors: Li, J. 
Wong, W.K.
Keywords: Bovine collagen treatment
Cross-validation
Longitudinal data
Rheumatic diseases
Semi-parametric model
Varying coefficient partly linear model
Issue Date: Mar-2009
Citation: Li, J., Wong, W.K. (2009-03). A semi-parametric analysis for identifying Scleroderma patients responsive to an anti-fibrotic agent. Contemporary Clinical Trials 30 (2) : 105-113. ScholarBank@NUS Repository. https://doi.org/10.1016/j.cct.2008.10.003
Abstract: In a recently concluded multi-center two-armed clinical trial for Scleroderma patients, results from a variety of analyses based on parametric models showed that late phase patients benefited from the bovine collagen treatment at 15 months and the placebo group did not. However, the cutoff time for defining early or late phase patients was somewhat arbitrary and sample size for late phase patients was small in the two groups. We apply a combination of semi-parametric and parametric approaches to further ascertain treatment efficacy and address modeling issues related to the choice of the cutoff and the scientific hypothesis of interest. We compare results with those obtained from parametric models and demonstrate how semi-parametric methods can help to better identify Scleroderma patients responsive to an anti-fibrotic agent. © 2008 Elsevier Inc. All rights reserved.
Source Title: Contemporary Clinical Trials
URI: http://scholarbank.nus.edu.sg/handle/10635/104966
ISSN: 15517144
DOI: 10.1016/j.cct.2008.10.003
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

8
checked on Nov 11, 2019

WEB OF SCIENCETM
Citations

7
checked on Nov 11, 2019

Page view(s)

48
checked on Nov 9, 2019

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.